Glecaprevir and pibrentasvir combination therapy for hepatitis C virus-infected Japanese patients on hemodialysis

Table 1 Patient baseline clinical characteristics

Characteristics		All patients
N		18
Age	Years	67.5 (48–84)
Sex, male	n (%)	14 (77.8)
Duration of hemodialysis	Years	2.7 (0.3–30)
Etiology of end-stage renal disease	n (%)
Diabetic nephropathy		9 (50.0)
Hypertensive kidney disease		5 (27.8)
Glomerulonephritis		2 (11.1)
Others		2 (11.1)
Weight	kg	65.5 (46.0–81.5)
HCV genotype	n (%)
1b		9 (50.0)
2a		6 (33.3)
2b		3 (16.7)
HCV treatment history	n (%)
Naïve		14 (77.8)
Interferon-based therapy		3 (18.8)
Interferon-free therapy: daclatasvir and asunaprevir		3 (18.8)
Liver cirrhosis	n (%)	4 (22.2)
Serum HCV-RNA levels	Log₁₀IU/ml	6.55 (4.1–7.3)
Baseline polymorphisms	n (%)
NS3/4 only		0
NS5A only		0
Both NS3 and NS5A		3 (16.7)
Laboratory data
Hemoglobin	g/dL	11.8 (9.9–14.5)
White blood cell	/μl	5650 (3300–8000)
Platelets	× 10⁴/μl	17.4 (6.2–27.8)
Aspartate aminotransferase	IU/L	20 (9–162)
Alanine aminotransferase	IU/L	16 (5.0–168)
Total protein	g/dL	7.3 (6.0–8.7)
Serum albumin	g/dL	4.0 (2.4–4.5)
Blood urea nitrogen	mg/dL	41.0 (19.9–63.0)
Creatinine	mg/dL	8.6 (4.4–13.0)
Total bilirubin	mg/dL	0.4 (0.2–0.9)
Hemoglobin A1c	%	5.7 (4.3–8.8)
Alpha-fetoprotein	ng/ml	2.0 (1–4.8)
M2BPGi	C.O.I	1.9 (0.52–19)

ISSN: 2059-1381